UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040872
Receipt number R000046670
Scientific Title Effects of MIYA-BM for clinical symptoms and gut microbiome in patients with chronic constipation.
Date of disclosure of the study information 2020/06/23
Last modified on 2024/04/20 09:56:00

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of MIYA-BM for clinical symptoms and gut microbiome in patients with chronic constipation.

Acronym

Effects of MIYA-BM for clinical symptoms and gut microbiome in patients with chronic constipation.

Scientific Title

Effects of MIYA-BM for clinical symptoms and gut microbiome in patients with chronic constipation.

Scientific Title:Acronym

Effects of MIYA-BM for clinical symptoms and gut microbiome in patients with chronic constipation.

Region

Japan


Condition

Condition

Chronic constipation

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to explore unknown possibilities of probiotics for the treatment of chronic constipation, evaluating the clinical efficacy of MIYA-BM and its effects for gut microbiome in patients with chronic constipation.

Basic objectives2

Others

Basic objectives -Others

Probiotics is proposed to be used as one of the useful treatments for chronic constipation in the Japanese Guideline for the Management of Chronic Constipation. The aim of this study is to explore unknown possibilities of probiotics for the treatment of chronic constipation, evaluating the clinical efficacy of MIYA-BM and its effects for gut microbiome in patients with chronic constipation.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Symptomatic improvement of chronic constipation evaluated with Constipation Scoring System

Key secondary outcomes

1,Improvement of constipation specific quality of life evaluated with Japanese version of Patient Assessment of Quality of Life questionnaire (JPAC-QOL)
2,The comparison of bowel movement
3,The comparison of stool consistency
4,The comparison of gut microbiome


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1, Patients who visited our department, seeking for treatment of constipation.
2, The score of Constipation Scoring System (0: no symptoms - 30: worst symptoms) is 5 or over.
3, Patients who can promise that they do not start or increase the dosage of medication for chronic constipation while they take MIYA-BM for 28-35 days in this study.

Key exclusion criteria

1, Patients who took MIYA-BM within one month before entering this study.
2, Pregnant or lactating woman.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Toshiki
Middle name
Last name Mimura

Organization

Jichi Medical University

Division name

Division of Gastroenterological, General and Transplant Surgery, Department of Surgery

Zip code

329-0498

Address

3311-1 Yakushiji Shimotsuke-shi,Tochigi

TEL

0285-58-7371

Email

mimurat@jichi.ac.jp


Public contact

Name of contact person

1st name Yuko
Middle name
Last name Homma

Organization

Jichi Medical University

Division name

Division of Gastroenterological, General and Transplant Surgery, Department of Surgery

Zip code

329-0498

Address

3311-1 Yakushiji Shimotsuke-shi,Tochigi

TEL

0285-58-7371

Homepage URL


Email

y.homma@jichi.ac.jp


Sponsor or person

Institute

Jichi Medical University
Division of Gastroenterological, General and Transplant Surgery, Department of Surgery

Institute

Department

Personal name



Funding Source

Organization

MIYARISAN PHARMACEUTICAL CO. LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Jichi Medical University Hospital Bioethics Committee for Clinical Research

Address

3311-1 Yakushiji Shimotsuke-shi,Tochigi

Tel

0285587371

Email

rinri@jichi.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

自治医科大学病院(栃木県)


Other administrative information

Date of disclosure of the study information

2020 Year 06 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2020 Year 02 Month 18 Day

Date of IRB

2020 Year 03 Month 16 Day

Anticipated trial start date

2020 Year 06 Month 16 Day

Last follow-up date

2025 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2026 Year 03 Month 31 Day


Other

Other related information

The subjects are patients who visited our department, seeking for treatment of constipation. Their constipation symptoms and gut microbiome are to be compared before and after taking MIYA-BM for 4-5 weeks.


Management information

Registered date

2020 Year 06 Month 23 Day

Last modified on

2024 Year 04 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046670


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name